Suppr超能文献

VITA-D:维生素D缺乏的肾移植受者中胆钙化醇替代治疗:一项评估移植后结局的随机、安慰剂对照研究

VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome.

作者信息

Thiem Ursula, Heinze Georg, Segel Rudolf, Perkmann Thomas, Kainberger Franz, Mühlbacher Ferdinand, Hörl Walter, Borchhardt Kyra

机构信息

Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

出版信息

Trials. 2009 May 29;10:36. doi: 10.1186/1745-6215-10-36.

Abstract

BACKGROUND

Vitamin D does not only regulate calcium homeostasis but also plays an important role as an immune modulator. It influences the immune system through the induction of immune shifts and regulatory cells resulting in immunologic tolerance. As such, vitamin D is thought to exert beneficial effects within the transplant setting, especially in kidney transplant recipients, considering the high prevalence of vitamin D deficiency in kidney transplant recipients.

METHODS/DESIGN: The VITA-D study, a randomized, placebo-controlled, double-blind study with two parallel groups including a total of 200 kidney transplant recipients, is designed to investigate the immunomodulatory and renoprotective effects of cholecalciferol (vitamin D3) within the transplant setting. Kidney transplant recipients found to have vitamin D deficiency defined as 25-hydroxyvitamin D3 < 50 nmol per liter will be randomly assigned to receive either oral cholecalciferol therapy or placebo and will be followed for one year. Cholecalciferol will be administered at a dose of 6800 International Units daily over a time period of one year. The objective is to evaluate the influence of vitamin D3 substitution in vitamin D deficient kidney transplant recipients on the post-transplant outcome. As a primary endpoint glomerular filtration rate calculated with the MDRD formula (modification of diet in renal disease) one year after kidney transplantation will be evaluated. Incidence of acute rejection episodes, and the number and severity of infections (analyzed by means of C-reactive protein) within the first year after transplantation will be monitored as well. As a secondary endpoint the influence of vitamin D3 on bone mineral density within the first year post-transplant will be assessed. Three DXA analyses will be performed, one within the first four weeks post-transplant, one five months and one twelve months after kidney transplantation.

摘要

背景

维生素D不仅调节钙稳态,还作为免疫调节剂发挥重要作用。它通过诱导免疫转变和调节性细胞影响免疫系统,从而产生免疫耐受。因此,考虑到肾移植受者中维生素D缺乏的高发生率,维生素D被认为在移植环境中发挥有益作用,尤其是在肾移植受者中。

方法/设计:VITA-D研究是一项随机、安慰剂对照、双盲研究,有两个平行组,共纳入200名肾移植受者,旨在研究胆钙化醇(维生素D3)在移植环境中的免疫调节和肾脏保护作用。被发现维生素D缺乏(定义为25-羟基维生素D3<50 nmol/L)的肾移植受者将被随机分配接受口服胆钙化醇治疗或安慰剂,并随访一年。胆钙化醇将在一年内每天以6800国际单位的剂量给药。目的是评估维生素D缺乏的肾移植受者补充维生素D3对移植后结局的影响。作为主要终点,将评估肾移植一年后用MDRD公式(肾脏病饮食改良)计算的肾小球滤过率。还将监测移植后第一年内急性排斥反应的发生率以及感染的数量和严重程度(通过C反应蛋白分析)。作为次要终点,将评估维生素D3对移植后第一年内骨密度 的影响。将进行三次双能X线吸收测定分析,一次在移植后前四周内,一次在肾移植后五个月,一次在十二个月后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba64/2701431/c5c6424920be/1745-6215-10-36-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验